ArticleMagyar onkologia2025
[Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 5th Hungarian Consensus Conference on Breast Cancer].
Article in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following a wide interdisciplinary consultation, the present recommendations have been finalized after their public discussion at the 5th Hungarian Consensus Conference on Breast Cancer. The recommendations cover non-operative, intraoperative and postoperative diagnostics, the determination of prognostic and predictive markers and the content of the cytology and histology reports. Furthermore, it touches some special issues such as the current status of multigene molecular markers, the role of pathologists in clinical trials and prerequisites for their involvement. The most important changes include the integration of the ASCO/CAP HER2 assessment guidelines from 2023, the reformulation of the role of cytology in breast cancer diagnostics, diagnostic categories of non-operative lymph node assessment, and the revision of PD-L1 assessment related information. The recommendations include the core and non-core elements of the ICCR (International Collaboration on Cancer Reporting) breast cancer related datasets.
Indexed as
Identifiers
41002085PMC12495542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.